NICE technology appraisal guidance
Issued: April 2012
TA252

Telaprevir for the treatment of genotype 1 chronic hepatitis C

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta252

1 Guidance

1.1 Telaprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:

  • who are previously untreated or

  • in whom previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin has failed, including people whose condition has relapsed, has partially responded or did not respond.